Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Surg Res. 2013 Jul;183(1):204-13. doi: 10.1016/j.jss.2012.11.048. Epub 2012 Dec 20.
Implantation-associated infections have increased significantly with the recent widespread use of medical implants. Treatments for these infections are not always successful because these infections are sometimes caused by multiantibiotic-resistant organisms. It is therefore particularly urgent to provide doctors with more effective antimicrobial agents against these antibiotic-resistant organisms. Human β-defensin 3 (hBD-3) has been shown to have strong broad-spectrum antibacterial activity. However, its effect on methicillin-resistant Staphylococcus epidermidis (MRSE) and methicillin-resistant Staphylococcus aureus (MRSA) in medical implant biofilm formation has not been reported.
In this study, we evaluated the effects of hBD-3 on S epidermidis ATCC 35984 (methicillin-resistant strain), MRSE287, and MRSA (ATCC43300) by evaluating bacterial adhesion, biofilm formation, and maturation. In addition, we used the spread plate method, confocal laser scanning microscopy, scanning electron microscopy, and real-time polymerase chain reaction to evaluate the effect of hBD-3.
After evaluating biofilm adhesion and formation, we found that the number of each strain on the titanium surface was decreased in those groups exposed to 1MIC (minimum inhibitory concentration) of hBD-3 and was significantly lower than the number of colonies of the control. In the initial maturation of the biofilm, the numbers of each strain on the titanium surface from the 2MIC to 6MIC groups were significantly lower than the control. When the concentrations were further increased, hBD-3 was significantly effective against drug-resistant bacteria from the biofilms.
HBD-3 has the potential to eliminate the biofilm formation of Staphylococcus, especially antibiotic-resistant strains, effectively.
随着近年来医疗植入物的广泛应用,与植入物相关的感染显著增加。这些感染的治疗并不总是成功的,因为这些感染有时是由多抗生素耐药生物引起的。因此,为医生提供针对这些抗生素耐药生物的更有效的抗菌剂尤为紧迫。人β-防御素 3(hBD-3)已显示出具有强大的广谱抗菌活性。然而,其对耐甲氧西林表皮葡萄球菌(MRSE)和耐甲氧西林金黄色葡萄球菌(MRSA)在医疗植入物生物膜形成中的作用尚未报道。
在这项研究中,我们通过评估细菌粘附、生物膜形成和成熟度,评估了 hBD-3 对 S 表皮葡萄球菌 ATCC 35984(耐甲氧西林株)、MRSE287 和 MRSA(ATCC43300)的影响。此外,我们使用了平板扩散法、共聚焦激光扫描显微镜、扫描电子显微镜和实时聚合酶链反应来评估 hBD-3 的效果。
在评估生物膜粘附和形成后,我们发现暴露于 1MIC(最低抑菌浓度)的 hBD-3 的钛表面上的每种菌株的数量减少,并且明显低于对照的菌落数。在生物膜的初始成熟阶段,钛表面上的每种菌株的数量从 2MIC 到 6MIC 组明显低于对照。当浓度进一步增加时,hBD-3 对生物膜中的耐药菌具有显著的效果。
hBD-3 具有有效消除葡萄球菌生物膜形成的潜力,特别是抗生素耐药株。